

2016

# Dietary Total Isoflavone Intake Is Associated With Lower Systolic Blood Pressure: The Coronary Artery Risk Development in Young Adults (CARDIA) Study

S. I. Richardson

*Zucker School of Medicine at Hofstra/Northwell*

L. M. Steffen

K. Swett

C. Smith

L. Burke

*See next page for additional authors*

Follow this and additional works at: <https://academicworks.medicine.hofstra.edu/articles>



Part of the [Internal Medicine Commons](#)

---

## Recommended Citation

Richardson S, Steffen L, Swett K, Smith C, Burke L, Zhou X, Shikany J, Rodriguez C. Dietary Total Isoflavone Intake Is Associated With Lower Systolic Blood Pressure: The Coronary Artery Risk Development in Young Adults (CARDIA) Study. . 2016 Jan 01; 18(8):Article 2130 [ p.]. Available from: <https://academicworks.medicine.hofstra.edu/articles/2130>. Free full text article.

This Article is brought to you for free and open access by Donald and Barbara Zucker School of Medicine Academic Works. It has been accepted for inclusion in Journal Articles by an authorized administrator of Donald and Barbara Zucker School of Medicine Academic Works. For more information, please contact [academicworks@hofstra.edu](mailto:academicworks@hofstra.edu).

---

**Authors**

S. I. Richardson, L. M. Steffen, K. Swett, C. Smith, L. Burke, X. Zhou, J. M. Shikany, and C. J. Rodriguez



Published in final edited form as:

*J Clin Hypertens (Greenwich)*. 2016 August ; 18(8): 778–783. doi:10.1111/jch.12760.

## Dietary Total Isoflavone Intake is Associated with Lower Systolic Blood Pressure: the Coronary Artery Risk Development in Young Adults (CARDIA) Study

Safiya I. Richardson<sup>1</sup>, Lyn M. Steffen<sup>2</sup>, Katrina Swett<sup>3</sup>, Che Smith<sup>3</sup>, Lora Burke<sup>4</sup>, Xia Zhou<sup>2</sup>, James M. Shikany<sup>5</sup>, and Carlos J. Rodriguez<sup>3</sup>

<sup>1</sup>Hofstra North Shore-LIJ School of Medicine, Department of Medicine Manhasset, NY

<sup>2</sup>University of Minnesota, Division of Epidemiology and Community Health Minneapolis, MN

<sup>3</sup>Wake Forest School of Medicine, Division of Public Health Sciences Winston-Salem, NC

<sup>4</sup>University of Pittsburgh School of Nursing Pittsburgh, PA

<sup>5</sup>University of Alabama at Birmingham, Division of Preventive Medicine Birmingham, AL

### Abstract

The effect of dietary isoflavone intake on systolic blood pressure (SBP) has not been studied in a large community-based cohort inclusive of African Americans.

We analyzed data from the year 20 exam of the Coronary Artery Risk Development in Young Adults (CARDIA) study, including medical history, physical exam and dietary intake surveys for 3,142 participants. Multivariable linear regression models controlled for age, sex, BMI, smoking, physical activity, and intakes of alcohol and total energy. Effect modification by race was tested.

Overall, those with hypertension had a lower daily intake of total dietary isoflavones ( $2.2 \pm 5.2$  vs.  $4.1 \pm 11.7$  mg/day;  $p$ -value  $< 0.001$ ). In fully adjusted models, the highest quartile of dietary isoflavone intake was associated with a 4.4 mmHg lower SBP on average compared with SBP for the lowest quartile. The relation between dietary isoflavone intake and SBP was more pronounced among African Americans, compared to Caucasians ( $p$ -for interaction  $< 0.001$ ).

Greater dietary intake of isoflavones was independently associated with a lower SBP.

### Keywords

hypertension; blood pressure; isoflavone; soy; diet; African American; epidemiology

### Introduction

Elevated blood pressure (BP) is a major public health concern. According to recent National Health and Nutrition Examination Survey (NHANES) data, approximately 29.3% of

Corresponding author: Carlos J. Rodriguez MD, MPH, Wake Forest University School of Medicine, Medical Center Blvd, Winston-Salem, N.C. 27157, 336-713-1648 (OFFICE), crodrigu@wakehealth.edu.

Disclosures: None

American adults have a diagnosis of hypertension.<sup>1</sup> Of these, only about half are being treated adequately.<sup>1</sup> This has a significant negative impact on the health of the nation with hypertension contributing to one out of every seven deaths in the United States. A health care system that could better treat the remaining half of hypertensives could avoid 46,000 deaths and direct and indirect costs of more than \$93.5 billion per year.<sup>2,3</sup>

The impact of dietary composition in treating hypertension was demonstrated by the Dietary Approaches to Stop Hypertension (DASH) trial in 2001, where the DASH diet, with an intermediate sodium level, led to a 5.0 mmHg lower mean systolic blood pressure (SBP) compared with the control diet.<sup>4</sup> Intervention studies examining the BP lowering effect of supplemental soy protein have suggested similar efficacy. Soy protein supplementation of 20 – 40 g per day has been shown in relatively small, randomized, controlled trials to lower BP in select populations.<sup>5–7</sup> Isoflavones, the suspected active ingredients in soy, were directly evaluated in a recent meta-analysis of 14 randomized controlled trials with a total of 789 non-hypertensive participants ingesting 25–375 mg of soy isoflavones for 2–24 weeks where SBP decreased, on average, by 1.9 mmHg.<sup>8</sup> A separate meta-analysis inclusive of hypertensive participants showed a larger effect of isoflavones on SBP among hypertensives with a 5.9 mmHg reduction on average.<sup>9</sup>

The relation between dietary isoflavone intake and BP has not been studied in a population-based cohort inclusive of African Americans. This is a group, that when compared to Caucasians, is at higher risk for hypertension, with an earlier onset, and more associated severe end-organ damage, including left ventricular hypertrophy, renal failure, and stroke.<sup>10,11</sup> Our hypothesis was that there would be an inverse and dose-response relationship between dietary isoflavone intake and SBP, and this relationship would be modified by race.

## Methods

The Coronary Artery Risk Development in Young Adults (CARDIA) Study is a prospective study investigating the development and determinants of subclinical and clinical cardiovascular disease. The study began in 1985-6 and enrolled 5,115 African American and Caucasian men and women aged 18–30 years. Participants were selected so that there would be approximately the same number of people in subgroups of race, gender, education and age in each of four centers: Birmingham, AL; Chicago, IL; Minneapolis, MN; and Oakland, CA. These participants were asked to attend follow-up examinations during years 2, 5, 7, 10, 15, 20, and 25. This cross-sectional study is limited to participants with non-missing BP measurements and dietary data at year 20 (n = 3,142).

At the CARDIA year 20 exam, demographic information and other characteristics were collected from questionnaires and clinical measurements were performed. Age, gender, and smoking habits were ascertained through questionnaires. Positive smoking history was defined as daily smoking in adolescence and/or in adulthood. Body weight was measured with light clothing to the nearest 0.2 lbs. Body height without shoes was measured to the nearest 0.5 cm. Body mass index (BMI) was calculated from these measurements ( $\text{kg}/\text{m}^2$ ). Physical activity was measured using the interviewer-administered CARDIA Physical

Activity questionnaire. The questionnaire asks about participation in 13 specific moderate and vigorous intensity activities over the previous year, including sports, exercise, home maintenance, and occupational activities. Each activity was assigned an intensity score (ranging from 3–8 metabolic equivalents) and a duration threshold (ranging from 2–5 hours/week) to calculate a total activity score. For an approximate reference, a total activity score of 300 exercise units approximates at least 150 minutes of moderate intensity activity per week.<sup>12</sup> Hypertensive participants (defined as participants with SBP > 140 mmHg and DBP > 90 mmHg based on three BP measurements, after 5 minutes seated at rest, obtained with an Omron oscillometer; or by a self-reported history of physician-diagnosed hypertension; or known to be taking antihypertensive medication) were included in this analysis.

At year 20, dietary intake was assessed by the interviewer-administered CARDIA Diet History, a validated dietary assessment tool querying 100 food questions, frequency, and portion size (including open-ended responses within each food question) to quantify daily nutrient and food intake.<sup>13,14</sup> Nutrient values were calculated based on frequency and portion size of food consumed and using the diet data entry software Nutrition Data System for Research (NDSR), developed at the University of Minnesota Nutrition Coordinating Center. Dietary sodium intake includes naturally occurring sodium in foods as well as that added during food processing. It does not include sodium from salt added at the table. Sodium values are in milligrams (mg). Intake of isoflavones daidzein, genistein and glycitein were summed for total isoflavone intake using NDSR methodology based on food table-derived isoflavone values in the USDA Database for the Isoflavone Content of Selected Foods.<sup>15</sup> Quartiles of total isoflavone intake (mg/day) were created to evaluate for a possible dose-response relation with BP. Total isoflavone intake quartiles were defined as: Q1: 0 – 0.33 mg/day; Q2: 0.34 – 0.73 mg/day; Q3: 0.74 – 2.50 mg/day; Q4: 2.51 – 222.27 mg/day. Total energy (caloric) intake was calculated for each participant.

### Statistical Analysis

Year 20 characteristics were computed as means (SD) or frequencies (%) and differences tested using t tests or chi-square statistics, respectively, with the significance level set at  $p < 0.05$ . Characteristics of participants at each quartile of dietary isoflavone intake were compared using ANOVA. Linear regression models for the overall cohort were fit to assess the association between SBP and daily total dietary isoflavone intake. A minimally adjusted linear regression model included age and sex only while our fully adjusted multivariable model included age, sex, BMI, smoking, physical activity and intakes of alcohol, sodium and total energy. Effect modification by race on the relationship between dietary isoflavone intake and SBP was tested by including the product total dietary isoflavone intake\*race term in the model. In the presence of a significant interaction ( $p$  for interaction  $< 0.05$ ), we performed a stratified analysis by race. We performed the following sensitivity analyses: 1. adjustment for education/income; 2. adjustment for animal protein or vegetable protein intake; 3. adjustment for potassium or fiber intake; 4. adjustment for dietary supplement use; and 5. adjustment for anti-hypertensive medication use. All analyses were performed using SAS version 9.3.4 (SAS Institute, Inc., Cary, North Carolina).

## Results

The cohort was young to middle-aged, 56.9% female and 46.6% African American. (Table 1) Less than 20% of the cohort had less than a high school education. Over a third of participants were either current or former smokers and over a third of the cohort was obese. Mean SBP for all participants was 115.5 mmHg. One-quarter of the cohort was hypertensive with African American participants having twice the prevalence than Caucasians (36.5% vs. 18.4%;  $p < .0001$ ). Dietary isoflavone intake was significantly higher (by about 1.7 mg) among Caucasians ( $p < 0.001$ ) versus African Americans and among those with higher education versus lower education ( $p < 0.001$ ). Mean values for dietary intake of soy isoflavones in quartile 1, quartile 2, quartile 3, and quartile 4 were 0.2, 0.5, 1.3 and 13.8 mg/day, respectively. In the highest quartile of dietary isoflavone intake compared to the lowest intake, there were fewer obese individuals and adults tended to be more physically active. (Table 2)

An inverse, age-sex-energy intake adjusted, dose-response relationship was observed with dietary isoflavone intake and SBP, where each additional 10 mg of average dietary isoflavone consumption amounted to an average decrease of 1.0 mmHg in SBP. (Table 3) Being in the highest quartile of dietary isoflavone intake compared to the lowest was associated with a 5.8 mmHg lower SBP ( $p < 0.0001$ ). (Table 4) In fully adjusted models all relationships persisted, although attenuated, as being in the highest quartile of dietary isoflavone intake was associated with a 4.3 mmHg lower SBP ( $p < 0.0001$ ). Further adjustment in sensitivity analysis for education, income, antihypertensive medication use, dietary supplement use, vegetable protein intake, animal protein intake, and fiber or potassium intake did not significantly affect the results (data not shown).

A statistically significant interaction was noted for dietary isoflavone intake and SBP by race ( $p$  for interaction  $< 0.001$ ); therefore we examined the dietary isoflavone-SBP relation stratified by race. African American participants demonstrated significantly lower SBP with higher dietary isoflavone intake compared to Caucasians. Each additional 10 mg of average dietary isoflavone consumption amounted to an average decrease of 1.0 mmHg in SBP among African Americans ( $p = 0.02$ ) whereas only an average decrease of 0.1 mmHg in SBP among Caucasians ( $p = 0.76$ ). Among African Americans, in age-sex adjusted models, there was a significant 4.4 mmHg lower SBP comparing the highest quartile of dietary isoflavone intake to the lowest ( $p < 0.05$ ); 3.7 mmHg lower SBP in fully adjusted models. (Table 4) Caucasians did not exhibit such a graded relationship between dietary isoflavone intake and SBP with a non-statistically significant 1.6 mmHg lower SBP in age-sex adjusted models comparing the highest quartile of dietary isoflavone intake to the lowest which did not change appreciably in fully adjusted models.

## Discussion

This is the first study to examine the effect of dietary isoflavone intake in a community-based cohort, and separately among Caucasians and African-Americans. Our findings show that SBP was 4.3 mmHg lower among those consuming the highest amount of isoflavones. The association was independent of age, sex, BMI, smoking, physical activity and intakes of

alcohol, sodium and total energy intake. The results were modified by race, with a stronger benefit in African-Americans. This is a potentially important finding since African-Americans are at a higher risk for hypertension with an earlier onset that is associated with more severe end-organ damage, including left ventricular hypertrophy, renal failure and stroke compared to Caucasians.<sup>10,11</sup> Our results have major implications for BP lowering on a population basis since isoflavones are readily available in several soy products. Dietary modalities to lower BP are important because they are less costly than medications and adherence may be better.

The consumption of soy protein is currently encouraged by the Food and Drug Administration, who support the claim that 25 grams per day of soy protein, included in a diet low in saturated fat and cholesterol, may reduce the risk of coronary heart disease.<sup>16</sup> This recommendation is based on a meta-analysis of studies that found an association between increased soy intake and more favorable lipid profiles, specifically lower serum LDL and triglycerides and higher serum HDL.<sup>17</sup> Our data suggest that intake of isoflavones (organic compounds found primarily in soy) is associated with a significant BP lowering effect. This association was independent of age, sex, weight, smoking, alcohol, physical activity, sodium contained in the food, and total energy intake. SBP was, on average, 4.3 mmHg lower among those who consumed the highest amount of dietary isoflavones compared to those who consumed the least amount, indicating a potentially significant additional cardiovascular benefit from dietary soy intake.

The effect of soy protein on BP has been previously evaluated in randomized controlled trials. In a study of 300 pre-hypertensive and untreated hypertensive Chinese adults, participants randomized to 40 grams per day of isolated soybean protein supplement in the form of cookies showed a greater decrease in SBP than controls who received 40 grams of complex carbohydrate.<sup>5</sup> The effect was particularly prominent among hypertensives where the SBP in the intervention group was 7.9 mmHg lower, compared to 2.3 mmHg among those without hypertension. In another study, 60 healthy, postmenopausal women were randomized to eight weeks of either a Therapeutic Lifestyle Changes diet (consisting of 30% energy from total fat, 15% energy from protein, 55% energy from carbohydrate, plus 1200 mg calcium per day and 2 fatty fish meals per week) alone or one in which soy nuts (containing 25 grams of soy protein and 101 mg of aglycone isoflavones) replaced 25 grams of non-soy protein.<sup>6</sup> The soy protein diet lowered SBP by 9.9% in hypertensives and 5.2% in normotensives compared to baseline SBP values. In a double blind randomized trial of 40 hypertensive men and women, soymilk (500 mL twice a day for 3 months) in place of cow's milk was associated with an SBP decrease of 17 mmHg.<sup>7</sup> In a recent meta-analysis of fourteen randomized controlled trials with a total of 789 normotensive participants ingesting 25–375 mg of soy isoflavones for 2–24 weeks, SBP decreased, on average, by 1.9 mmHg.<sup>8</sup> A separate meta-analysis by Liu, et al<sup>9</sup> of eleven trials with isoflavones daily intake 65–153 mg, actually included hypertensives and showed a significant, larger effect of soy on SBP lowering among hypertensives (5.9 mmHg).

Isoflavones, the suspected active ingredients in soy, are found in green tea, peanuts, tofu and other plant foods. The mechanism behind the BP lowering effect seen here that might be attributed to isoflavones could be through the activation of endothelial nitric oxide synthase

(eNOS) and stimulation of nitric oxide (NO) production. Endothelial cells generate the potent vasodilator NO from L-arginine using NO synthases. Genistein, one of the primary isoflavones found in soy has been demonstrated to have direct non-genomic effects on eNOS activity in human aortic endothelial cells, leading to eNOS activation and nitric oxide synthesis.<sup>18</sup> In healthy Caucasian postmenopausal women, increased soy consumption has been associated with higher plasma concentrations of NO.<sup>19</sup>

What may support NO as a possible mechanism for our findings is our finding of a stronger correlation between increased dietary isoflavone intake and lower SBP among African Americans. Most prior studies do not mention, and probably didn't assess, racial make-up. It is unlikely that prior studies did not have a 46% African American constituency as we did. The inclusion of African Americans in our cohort likely drives the larger effects size seen for isoflavone intake on SBP lowering. Among hypertensives and normotensives, African Americans have been shown to exhibit relative endothelial dysfunction compared to Caucasians, which is marked by decreased endothelium-derived NO production and bioavailability.<sup>20–22</sup> Total eNOS protein appears to be increased in African Americans, but there is a lack of biologically active NO production.<sup>23</sup> It is possible that increased dietary isoflavone intake may indeed replete NO in this group, possibly altering the NO balance to help reverse the relative NO deficiency present in African Americans.

The importance of BP, especially SBP, as an independent risk factor for coronary events, stroke, heart failure, and chronic kidney disease is well known.<sup>24</sup> Observational studies document a progressive and continuous increase in risk as SBP rises above 115 mm Hg.<sup>25</sup> There are several lifestyle interventions that have consistently been shown to lower SBP. Moderate dietary salt restriction results in a fall in SBP in hypertensive and normotensive individuals by 5.0 and 2.0 mmHg, respectively.<sup>26</sup> Weight loss of about 5.1 kg was shown, in a meta-analysis of twenty-five trials, to be associated with a mean drop in SBP of 4.4 mmHg, where BP reductions were similar in hypertensive and normotensive subjects.<sup>27</sup> Meta-analysis of SBP reductions with increased potassium intake showed reductions of 4.4 and 1.8 mmHg in hypertensive and normotensive subjects, respectively.<sup>28</sup> Meta-analysis of fifteen randomized controlled trials demonstrated that decreased consumption of alcohol reduced SBP by 3.3 mmHg.<sup>29</sup>

In our study, high total dietary isoflavone intake was associated with a 4.3 mmHg lower SBP compared with low dietary isoflavone intake. This magnitude of effect, if supported by larger randomized controlled trials, would make increased dietary isoflavone intake similarly efficacious as dietary salt restriction or weight loss for controlling BP. Additionally, the high isoflavone content of soy products makes dietary supplementation a relatively effortless recommendation. An 8 oz. glass of soy milk contains 6 grams of soy protein and 22 mg of total isoflavones and 100g of roasted soybeans have as much as 35 grams of soy protein and 130 mg of total isoflavones. Of course, although diets rich in soy or soy-containing products appear safe and potentially beneficial, the long-term safety of high doses of soy isoflavones is not yet known.<sup>30</sup>

The strengths of our study include the large biracial population, standardized BP measurements, and assessment of dietary intake using the CARDIA Diet History. To our

knowledge, this is the first study to assess the relation of dietary isoflavone intake and BP in a community-based cohort and separately among Caucasians and African-Americans. We feel this difference is a significant part of what makes our findings interesting and noteworthy. The comprehensive population-based nature of our study increases the generalizability over prior smaller studies in select groups. There are however several limitations to our study. Cross-sectional studies do not establish a cause and effect relationship. One must take into account that there is no way to separate out soy intake from living a healthier lifestyle. There are possible unmeasured confounders that we could not control for; however, the dose-response relationship on SBP as isoflavone intake increases and the consistent results seen in several multivariable models argue against our results being due solely to confounding. Although genistein and daidzein are major phytonutrients found in soy food products, it is possible that other components found in soy or unidentified non-soy factors that covary with isoflavone exposure, could explain the observed decrease in BP. One cannot separate the chemical constituent from the whole food in this observational study, although our assessment of total isoflavone intake was food table-derived. Lastly, measurement error associated with nutrient estimates from the diet history could potentially underestimate any true association.

## Conclusion

Our results suggest a possible BP benefit of moderate dietary intake of isoflavone-rich foods, including soy and soy products. There may be an increased benefit for dietary intake of isoflavone-rich foods in African Americans. Our results have potential implications for BP lowering on a population basis and deserve further investigation. Because our finding was more pronounced in African Americans than in Caucasians, underrepresented minority participants should be included in future studies to better understand the association between isoflavone-rich food intake and BP.

## ACKNOWLEDGEMENTS

The Coronary Artery Risk Development in Young Adults Study (CARDIA) is supported by contracts HHSN268201300025C, HHSN268201300026C, HHSN268201300027C, HHSN268201300028C, HHSN268201300029C, and HHSN268200900041C from the National Heart, Lung, and Blood Institute (NHLBI), the Intramural Research Program of the National Institute on Aging (NIA), and an intra-agency agreement between NIA and NHLBI (AG0005).

Sources of Funding: This work was partially supported by a grant from the National Heart, Lung, and Blood Institute (R01 HL104199, Epidemiologic Determinants of Cardiac Structure and Function among Hispanics: Carlos J. Rodriguez, MD, MPH Principal Investigator).

## References

1. Yoon PW, Gillespie CD, George MG, Wall HK. Centers for Disease C, Prevention. Control of hypertension among adults--National Health and Nutrition Examination Survey, United States, 2005–2008. *MMWR. Morbidity and mortality weekly report*. 2012; 61(Suppl):19–25.
2. Farley TA, Dalal MA, Mostashari F, Frieden TR. Deaths preventable in the US by improvements in use of clinical preventive services. *American journal of preventive medicine*. 2010; 38(6):600. [PubMed: 20494236]
3. Heidenreich PA, Trogon JG, Khavjou OA, et al. Forecasting the Future of Cardiovascular Disease in the United States A Policy Statement From the American Heart Association. *Circulation*. 2011; 123(8):933–944. [PubMed: 21262990]

4. Sacks FM, Svetkey LP, Vollmer WM, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. *New England Journal of Medicine*. 2001; 344(1):3–10. [PubMed: 11136953]
5. He J, Gu D, Wu X, Chen J, Duan X, Whelton P. Effect of soybean protein on blood pressure: a randomized, controlled trial. *Annals of internal medicine*. 2005; 143(1):1. [PubMed: 15998749]
6. Welty FK, Lee KS, Lew NS, Zhou JR. Effect of soy nuts on blood pressure and lipid levels in hypertensive, prehypertensive, and normotensive postmenopausal women. *Archives of internal medicine*. 2007; 167(10):1060. [PubMed: 17533209]
7. Rivas M, Garay RP, Escanero JF, Cia P, Alda JO. Soy milk lowers blood pressure in men and women with mild to moderate essential hypertension. *The Journal of nutrition*. 2002; 132(7):1900–1902. [PubMed: 12097666]
8. Taku K, Lin N, Cai D, et al. Effects of soy isoflavone extract supplements on blood pressure in adult humans: systematic review and meta-analysis of randomized placebo-controlled trials. *Journal of hypertension*. 2010; 28(10):1971–1982. [PubMed: 20577121]
9. Liu XX, Li SH, Chen JZ, et al. Effect of soy isoflavones on blood pressure: a meta-analysis of randomized controlled trials. *Nutrition, metabolism, and cardiovascular diseases : NMCD*. 2012; 22(6):463–470.
10. Saunders E. Hypertension in African-Americans. *Circulation*. 1991; 83(4):1465–1467. [PubMed: 2013166]
11. Mensah GA, Mokdad AH, Ford ES, Greenlund KJ, Croft JB. State of disparities in cardiovascular health in the United States. *Circulation*. 2005; 111(10):1233–1241. [PubMed: 15769763]
12. Hankinson AL, Daviglius ML, Bouchard C, et al. Maintaining a high physical activity level over 20 years and weight gain. *Jama*. 2010; 304(23):2603–2610. [PubMed: 21156948]
13. Liu K, Slattery M, Jacobs D Jr, et al. A study of the reliability and comparative validity of the cardia dietary history. *Ethnicity & disease*. 1993; 4(1):15–27. [PubMed: 7742729]
14. McDonald A, Van Horn L, Slattery M, et al. The CARDIA dietary history: development, implementation, and evaluation. *J Am Diet Assoc*. 1991; 91(9):1104–1112. [PubMed: 1918764]
15. Bhagwat, S.; Haytowitz, D.; Holden, J. USDA Database for the Isoflavone Content of Selected Foods (Release 2.0). U.S. Department of Agriculture. 2008. <http://www.ars.usda.gov/nutrientdata/isoflav>.
16. Food labeling: health claims; soy protein and coronary heart disease. Food and Drug Administration, HHS. Final rule. Federal register. 1999; 64(206):57700–57733. [PubMed: 11010706]
17. Anderson JW, Bush HM. Soy protein effects on serum lipoproteins: a quality assessment and meta-analysis of randomized, controlled studies. *Journal of the American College of Nutrition*. 2011; 30(2):79–91. [PubMed: 21730216]
18. Si H, Yu J, Jiang H, Lum H, Liu D. Phytoestrogen Genistein Up-Regulates Endothelial Nitric Oxide Synthase Expression Via Activation of cAMP Response Element-Binding Protein in Human Aortic Endothelial Cells. *Endocrinology*. 2012; 153(7):3190–3198. [PubMed: 22669896]
19. Hallund J, Bügel S, Tholstrup T, et al. Soya isoflavone-enriched cereal bars affect markers of endothelial function in postmenopausal women. *British Journal of nutrition*. 2006; 95(06):1120–1126. [PubMed: 16768834]
20. Perregaux D, Chaudhuri A, Rao S, et al. Brachial vascular reactivity in blacks. *Hypertension*. 2000; 36(5):866–871. [PubMed: 11082158]
21. Kahn DF, Duffy SJ, Tomasian D, et al. Effects of black race on forearm resistance vessel function. *Hypertension*. 2002; 40(2):195–201. [PubMed: 12154113]
22. Kalinowski L, Dobrucki IT, Malinski T. Race-specific differences in endothelial function: predisposition of African Americans to vascular diseases. *Circulation*. 2004; 109(21):2511–2517. [PubMed: 15159296]
23. Malinski T. Understanding nitric oxide physiology in the heart: a nanomedical approach. *Am J Cardiol*. 2005; 96(7B):13i–24i. [PubMed: 15979424]
24. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. *Hypertension*. 2003; 42(6):1206–1252. [PubMed: 14656957]

25. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. *Lancet*. 2002; 360(9349):1903–1913. [PubMed: 12493255]
26. He F, MacGregor G, Correspondence G. Effect of modest salt reduction on blood pressure: a meta-analysis of randomized trials. Implications for public health. *Journal of human hypertension*. 2002; 16(11):761–770. [PubMed: 12444537]
27. Neter JE, Stam BE, Kok FJ, Grobbee DE, Geleijnse JM. Influence of weight reduction on blood pressure a meta-analysis of randomized controlled trials. *Hypertension*. 2003; 42(5):878–884. [PubMed: 12975389]
28. Whelton PK, He J, Cutler JA, et al. Effects of oral potassium on blood pressure. Meta-analysis of randomized controlled clinical trials. *Jama*. 1997; 277(20):1624–1632. [PubMed: 9168293]
29. Xin X, He J, Frontini MG, Ogden LG, Motsamai OI, Whelton PK. Effects of alcohol reduction on blood pressure a meta-analysis of randomized controlled trials. *Hypertension*. 2001; 38(5):1112–1117. [PubMed: 11711507]
30. Sacks FM, Lichtenstein A, Van Horn L, et al. Soy protein, isoflavones, and cardiovascular health: an American Heart Association Science Advisory for professionals from the Nutrition Committee. *Circulation*. 2006; 113(7):1034–1044. [PubMed: 16418439]

**Table 1**

Demographic and Clinical Characteristics, Year 20: CARDIA

Variable (N = 3142)	Mean (SD) or % (N)
Age at Year 20 Exam (years)	45.2 (3.63)
% Female	56.9% (1788)
% African American	46.6% (1466)
Highest Degree (HS, Bachelors/Masters, Doctorate) (N = 3140)	80.7% (2521)
Total Isoflavone Intake (mg/day)	4.0 (11.3)
Physical Activity (Total Intensity Score) (N = 3132)	335.2 (274.78)
% Ever Smoked (N = 3119)	38.5% (1201)
Alcohol Consumption (mL/day) (N = 3080)	10.5 (21.72)
Body Mass Index (kg/m <sup>2</sup> ) (N = 3129)	29.4 (7.24)
<b>BMI (N=3129)</b>	
Underweight (BMI < 18.5 kg/m <sup>2</sup> )	0.9% (28)
Normal (18.5 kg/m <sup>2</sup> BMI < 25 kg/m <sup>2</sup> )	27.6% (863)
Overweight (25 kg/m <sup>2</sup> BMI < 30 kg/m <sup>2</sup> )	33.3% (1041)
Obese (BMI ≥ 30 kg/m <sup>2</sup> )	38.3% (1197)
Systolic Blood Pressure	115.5 (14.6)
% Hypertensive	26.8% (843)

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

**Table 2**

Mean (SD) or Frequency (%) of Participant Characteristics according to Dietary Isoflavone Intake at Year 20: CARDIA

Variable	Isoflavone Quartile 1 n=764	Isoflavone Quartile 2 n=801	Isoflavone Quartile 3 n=789	Isoflavone Quartile 4 n= 788
Age at Year 20 Exam (years)	44.8 (3.8)	45.2 (3.7)	45.2 (3.6)	45.6 (3.3)
% Female	64.8%	53.8%	47.4%	61.9%
% African American	67.4%	49.3%	39.2%	31.4%
Education (years)	14.4 (2.5)	14.7 (2.6)	15.0 (2.6)	15.9 (2.5)
Physical Activity (Total Intensity Score)	266.4 (241.3)	311.0 (265.2)	346.5 (269.0)	414.8 (299.0)
% Ever Smoked	32.9%	39.5%	43.9%	37.6%
Alcohol Consumption (mL/day)	8.7 (23.1)	9.9 (15.5)	13.5 (28.3)	10.0 (17.6)
Total Energy (kcal/day)	1948.6 (965.6)	2386.1 (1067.1)	2718.1 (1604.5)	2547.7 (1444.6)
Body Mass Index (kg/m <sup>2</sup> )	31.1 (7.5)	29.9 (7.3)	29.10 (6.5)	27.7 (6.2)
<b>BMI (N=3129)</b>				
Underweight (BMI < 18.5 kg/m <sup>2</sup> )	0.90%	0.90%	0.60%	1.20%
Normal (18.5 kg/m <sup>2</sup> BMI < 25 kg/m <sup>2</sup> )	21.10%	24.60%	26.70%	37.90%
Overweight (25 kg/m <sup>2</sup> BMI < 30 kg/m <sup>2</sup> )	27.40%	34.60%	37.90%	33.00%
Obese (BMI ≥ 30 kg/m <sup>2</sup> )	50.70%	39.90%	34.80%	28.00%

**Table 3**  
Total Dietary Isoflavone Intake Relative to Systolic Blood Pressure at Year 20: CARDIA

	Regression Coefficient	SE	P value	Regression Coefficient	SE	P value	Regression Coefficient	SE	P value		
Soy intake (per 10mg)	-1.1	0.2	<.0001	Soy intake (per 10mg)	-1.0	0.2	<.0001	Soy intake (per 10mg)	-0.6	0.22	0.007
				Age	0.4	0.1	<.0001	Age	0.3	0.07	<.0001
				Female Sex	-5.2	0.5	<.0001	Female Sex	-5.6	0.55	<.0001
				Total Energy Intake (kcal)	0.0003	0.0002	0.09	BMI (kg/m <sup>2</sup> )	0.5	0.04	<.0001
								Smoking	1.6	0.53	0.003
								Physical Activity Intensity Score	-0.00038	0.00096	0.69
								Alcohol (mL/day)	0.04	0.01	0.0008
								Total Energy Intake (kcal)	0.001	0.0005	0.008
								Sodium Intake (mg)	-0.0008	0.0003	0.007

**Table 4**  
Systolic Blood Pressure according to Quartile of Dietary Isoflavone Intake at Year 20: CARDIA, n=3142

	Beta Estimate (SE)					
	Overall		African Americans		Caucasians	
	Minimally Adjusted N = 3142	Fully Adjusted N = 3038	Minimally Adjusted N = 1465	Fully Adjusted N = 1403	Minimally Adjusted N = 1676	Fully Adjusted N = 1635
<b>Average Isoflavone Intake (mg/day)</b>						
<b>Q1 (0 – 0.33)</b>	--	--	--	--	--	--
<b>Q2 (0.34 – 0.73)</b>	-3.2 (0.7)**	-3.0 (0.7)**	-2.7 (1.0)*	-2.8 (1.1)*	-0.7 (1.0)	-0.5 (0.9)
<b>Q3 (0.74 – 2.50)</b>	-4.6 (0.7)**	-4.1 (0.7)**	-2.6 (1.1)*	-2.2 (1.2)	-2.0 (0.9)*	-2.1 (0.9)*
<b>Q4 (2.51 – 222.27)</b>	-5.8 (0.7)**	-4.3 (0.9)**	-4.4 (1.2)*	-3.7 (1.3)*	-1.6 (0.9)	-0.8 (0.9)

\* p-value<0.05;

\*\* p-value<0.0001;

Fully adjusted model controlled for age, sex, BMI, smoking, alcohol intake, physical activity, total energy and sodium intake